Clinical Trial Update: hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on a Phase 1/2 study evaluating hOKT3γ1 (Ala-Ala) with sirolimus and delayed tacrolimus in Type 1 diabetes patients receiving islet allogr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoglycemia
• Type 1 Diabetes Mellitus

Drugs mentioned

• Sirolimus (Sirolimus)
• Tacrolimus (Tacrolimus)
• hOKT3γ1 (Ala-Ala) (hOKT3γ1 (Ala-Ala))

Snippet

Sponsor: University of Minnesota | Conditions: Type 1 Diabetes, Hypoglycemia | Phase 1, Phase 2 | Status: COMPLETED